Moleculin Biotech, Inc.
Moleculin Biotech, Inc. (MBRX) Stock Overview
Key statistics and deep links to earnings, valuation, revenue, dividends, and more.
FMP · MBRX · as of Jun 9, 2026
Key Statistics
Explore Moleculin Biotech, Inc. Data
mbrx stock data · financialsFinancial Snapshot
Full FinancialsAnalyst Ratings & Price Target
Full ForecastTotal: 4 · Buy rate: 100.0%
Competitors & Peers
mbrx competitorsMBRX
ADAP
AIMD
APLM
ATHA
BLRXStock Performance
Full HistoryAbout Moleculin Biotech, Inc.
Moleculin Biotech, Inc. is a clinical-stage pharmaceutical company dedicated to advancing therapeutic candidates designed to combat highly aggressive cancers and viral infections. Their primary invest…
what is moleculin biotech, inc. · mbrx stock overview · moleculin biotech, inc. company profile · who is moleculin biotech, inc. ceo · mbrx NASDAQ · moleculin biotech, inc. headquarters · moleculin biotech, inc. business segments
About Stock Overview & Key Data
Moleculin Biotech, Inc. (MBRX) is a Healthcare company in the Biotechnology industry, listed on NASDAQ since Jun 2, 2016. As of the latest trading session, MBRX stock price is $2.47, with a market capitalization of $3.0M. The stock has returned -85.25% over the past 12 months and -25.38% year-to-date.
According to 4 Wall Street analysts, the consensus rating for Moleculin Biotech, Inc. stock is Buy, with an average 12-month price target of $—. In fiscal year 2025, Moleculin Biotech, Inc. reported revenue of — and net income of -$33.6M. For detailed data — including Moleculin Biotech, Inc. revenue history, earnings, dividends, and PE ratio — use the tabs above.
Frequently Asked Questions
As of the latest trading session, Moleculin Biotech, Inc. (MBRX) stock price is $2.47. The stock is traded on NASDAQ under the ticker symbol MBRX. The 52-week range is $1.79 – $24.00.